Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

被引:60
作者
Yatsu, T [1 ]
Tomura, Y [1 ]
Tahara, A [1 ]
Wada, K [1 ]
Kusayama, T [1 ]
Tsukada, J [1 ]
Tokioka, T [1 ]
Uchida, W [1 ]
Inagaki, O [1 ]
Iizumi, Y [1 ]
Tanaka, A [1 ]
Honda, K [1 ]
机构
[1] Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Pharmacol Labs, Cardiovasc Dis Res, Tsukuba, Ibaraki 3058585, Japan
关键词
conivaptan hydrochloride; congestive heart failure; vasopressin receptor antagonist; non-peptide; vasoconstriction; water retention;
D O I
10.1016/S0014-2999(99)00379-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The systemic hemodynamic and renal responses to conivaptan hydrochloride (YM087; 4'-(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)-2-phenylbenzanilide monohydrochloride), a vasopressin V-1A and V-2 receptor antagonist, were determined in pentobarbital-anesthetized dogs after 3, to 3 weeks of rapid right ventricular pacing. Congestive heart failure, characterized by decreases in first derivative of left ventricular pressure (left ventricular d P/dt(max)) and cardiac output, and increases in left ventricular end-diastolic pressure and total peripheral vascular resistance, was induced by chronic rapid right ventricular pacing at 260-280 beats/min. Intravenous administration of conivaptan (0.1 mg/kg) significantly increased left ventricular dP/dt(max) and cardiac output and significantly decreased left ventricular end-diastolic pressure and total peripheral vascular resistance. Conivaptan also increased urine flow and reduced urine osmolality by markedly increasing free water clearance. These results indicate that conivaptan produced hemodynamic improvement and marked aquaresis in dogs with congestive heart failure. Therefore, conivaptan may find clinical use in treating patients with congestive heart failure. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 41 条
[1]   RAPID VENTRICULAR PACING IN THE DOG - PATHOPHYSIOLOGIC STUDIES OF HEART-FAILURE [J].
ARMSTRONG, PW ;
STOPPS, TP ;
FORD, SE ;
DEBOLD, AJ .
CIRCULATION, 1986, 74 (05) :1075-1084
[2]   VASOCONSTRICTOR ROLE FOR VASOPRESSIN IN EXPERIMENTAL HEART-FAILURE IN THE RABBIT [J].
ARNOLDA, L ;
MCGRATH, BP ;
COCKS, M ;
JOHNSTON, CI .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (03) :674-679
[3]   SYSTEMIC AND REGIONAL EFFECTS OF VASOPRESSIN AND ANGIOTENSIN IN ACUTE LEFT-VENTRICULAR FAILURE [J].
ARNOLDA, L ;
MCGRATH, BP ;
JOHNSTON, CI .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (02) :H499-H506
[4]   CHRONIC ANGIOTENSIN-CONVERTING-ENZYME INHIBITION IMPROVES CARDIAC-OUTPUT AND FLUID BALANCE DURING HEART-FAILURE [J].
BRANDS, MW ;
ALONSOGALICIA, M ;
MIZELLE, HL ;
MONTANI, JP ;
HILDEBRANDT, DA ;
HALL, JE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (02) :R414-R422
[5]   CURRENT THERAPY OF THE FAILING HEART [J].
COHN, JN .
CIRCULATION, 1988, 78 (05) :1099-1107
[6]   PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
OLIVARI, MT ;
GARBERG, V ;
LURA, D ;
FRANCIS, GS ;
SIMON, AB ;
RECTOR, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) :819-823
[7]   CONTRIBUTION OF VASOPRESSIN TO VASOCONSTRICTION IN PATIENTS WITH CONGESTIVE-HEART-FAILURE - COMPARISON WITH THE RENIN-ANGIOTENSIN SYSTEM AND THE SYMPATHETIC NERVOUS-SYSTEM [J].
CREAGER, MA ;
FAXON, DP ;
CUTLER, SS ;
KOHLMANN, O ;
RYAN, TJ ;
GAVRAS, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (04) :758-765
[8]   RENAL RESPONSE TO CAPTOPRIL IN SEVERE HEART-FAILURE - ROLE OF FUROSEMIDE IN NATRIURESIS AND REVERSAL OF HYPONATREMIA [J].
DZAU, VJ ;
HOLLENBERG, NK .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (06) :777-782
[9]   NEURO-ENDOCRINE MANIFESTATIONS OF CONGESTIVE HEART-FAILURE [J].
FRANCIS, GS .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (02) :A9-A13
[10]  
Fujisawa G., 1993, Journal of the American Society of Nephrology, V4, P852